Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

BACKGROUND: Prodromal Alzheimer’s disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks produc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Egan, Michael F., Kost, James, Voss, Tiffini, Mukai, Yuki, Aisen, Paul S., Cummings, Jeffrey L., Tariot, Pierre N., Vellas, Bruno, van Dyck, Christopher H., Boada, Merce, Zhang, Ying, Li, Wen, Furtek, Christine, Mahoney, Erin, Mozley, Lyn Harper, Mo, Yi, Sur, Cyrille, Michelson, David
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6776078/
https://ncbi.nlm.nih.gov/pubmed/30970186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1812840
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars